Purdue Pharma to Be Sentenced, Paving Way for Opioid Settlement.

  • Published In: Claims Journal, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Knauth, Dietrich 3 of 3

Abstract

This article focuses on Purdue Pharma’s federal sentencing in New Jersey for charges of deceiving regulators and paying kickbacks to doctors to increase opioid sales. The sentencing will finalize a plea deal allowing Purdue to dissolve in bankruptcy and fund a $7.4 billion settlement aimed at compensating those harmed by the opioid epidemic, including an $865 million fund for individuals affected. Victims of the crisis expressed frustration with the settlement, arguing it is insufficient, while Purdue’s legal representatives maintain the agreement fulfills the company’s obligations despite limited funds. Purdue admitted to misconduct related to its marketing of OxyContin but no executives were charged in the current case. The company plans to emerge from bankruptcy as a nonprofit focused on opioid addiction treatment and overdose-reversal medicines. [Extracted from the article]

Additional Information

  • Source:Claims Journal. 2026/04, pN.PAG
  • Document Type:Article
  • Subject Area:History
  • Publication Date:2026
  • Accession Number:193318039
  • Copyright Statement:Copyright of Claims Journal is the property of Wells Media Group and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.